Abstract:Recent studies demonstrated a strong positive association between blood trimethylamine-N-oxide (TMAO) level and risk for cardiovascular disease. Dietary choline is converted to trimethylamine (TMA) by the gut bacteria, and TMA is then converted to TMAO in the liver, mainly by flavin containing monooxygenase 3 (Fmo3). To examine how FMO3 expression influences atherogenesis, we administered two different FMO3 or control antisense oligonucleotdies (ASOs) to apolipoprotein E (apoE) null mice for 15 weeks. During the last 12 weeks of the ASO treatment, the mice received a chow diet containing 1% choline to enhance TMA production. Hepatic FMO3 mRNA levels were decreased by 80% in mice that received either FMO3 ASO #1 or #2 versus those that received the control ASO. As expected, circulating TMA and TMAO levels were significantly increased and decreased, respectively, in the mice that received the two FMO3 ASOs versus the controls. Other observed changes in the FMO3 ASO-treated mice included: decreased plasma triglyceride, HDL, and glucose levels. Significantly increased VLDL/IDL/LDL cholesterol was observed only in FMO3 ASO #2-treated mice versus the controls. FMO3 ASO treatment increased circulating total bile acid levels by more than 2-fold. Compared to controls, serum markers of hepatic inflammation and necrosis (ALT, AST) were significantly increased in FMO3 ASO treated mice. Histological examination revealed obvious hepatic steatosis and increased inflammatory cell infiltration, suggesting that FMO3 abrogation may be a reasonable model for non-alcoholic steatohepatitis (NASH). We also found a significant increase in quantitative triglyceride and cholesterol content of these livers. Transcriptional profiling by microarrays showed increased hepatic expression of inflammatory genes in mice that received FMO3 ASOs versus the controls. In addition, a significant increase in spleen weight in these mice suggests increased systemic inflammation. Finally, FMO3 knockdown increased atherosclerosis by more than 50% when compared to controls (p < 0.01). This work demonstrates that blocking FMO3 activity has a major impact on liver physiology and atherosclerosis. Our study suggests a protective role for FMO3 in atherosclerosis and liver function.

FMO3-TMAO axis modulates the clinical outcome in chronic heart-failure patients with reduced ejection fraction: evidence from an Asian population

The correlation between plasma trimethylamine N-oxide level and heart failure classification in northern Chinese patients

Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value

Trimethyllysine, a Trimethylamine N-oxide Precursor, Predicts the Presence, Severity, and Prognosis of Heart Failure

Trimethylamine oxide: a potential target for heart failure therapy

Trimethylamine N-Oxide Levels Are Associated with Severe Aortic Stenosis and Predict Long-Term Adverse Outcome

Gut microbiota-dependent metabolite trimethylamine N-oxide (TMAO) and cardiovascular risk in patients with suspected functionally relevant coronary artery disease (fCAD)

Targeted Plasma Metabolomics Reveals Association of Acute Myocardial Infarction Risk with the Dynamic Balance Between Trimethylamine-N-oxide, Betaine, and Choline.

Trimethylamine-N-Oxide, a Metabolite Associated with Atherosclerosis, Exhibits Complex Genetic and Dietary Regulation

Association Between Microbiota-Dependent Metabolite Trimethylamine-N-Oxide and Type 2 Diabetes

Abstract MP02: Urinary Level of Trimethylamine-N-Oxide Predicts an Increased Risk of Coronary Heart Disease Among Urban Chinese Adults

Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target

Association between trimethylamine N-oxide and prognosis of patients with myocardial infarction: a meta-analysis

Distribution characteristics and diagnostic value of TMAO and its precursors in HFpEF and HFrEF

Urinary Levels of Trimethylamine‐N‐Oxide and Incident Coronary Heart Disease: A Prospective Investigation among Urban Chinese Adults

Association of Systemic Trimethyllysine with Heart Failure with Preserved Ejection Fraction and Cardiovascular Events.

Gut microbiota-derived trimethylamine-N-oxide: A bridge between dietary fatty acid and cardiovascular disease?

Prognostic Value of Plasma Trimethylamine N-Oxide Levels in Patients with Acute Ischemic Stroke

Abstract 18108: Decreased Fmo3 Expression is Associated With Increased Atherosclerosis and Impaired Liver Function in Apolipoprotein E Null Mice

From heart failure and kidney dysfunction to cardiorenal syndrome: TMAO may be a bridge

Gut microbial metabolite TMAO portends prognosis in acute ischemic stroke